Mandate

Vinge advises Manor Investment S.A. on investment in Rabbalshede Kraft AB (publ)

June 20, 2013

Vinge is advising Manor Investment S.A. in connection with its investment in Rabbalshede Kraft AB (publ). The investment is made through inter alia acquisition of newly issued shares of class B in a private placement, acquisition of 347,500 shares of class A from certain of the current main shareholders, and through acquisition of newly issued shares of class B in a rights issue. Manor is a private industrial company within the renewable energy sector providing long-term development capital to entrepreneurs and industrial projects in Europe aiming for the better use of energy and natural resources. Rabbalshede develops and operates wind power farms in Sweden, with a current portfolio of 26 wind turbines proprietarily managed, 14 turbines under construction and about 350 turbines in the procurement, application or planning phase. Closing of the transactions is subject to certain conditions precedent. Manor is advised by Treïs (www.treispartners.com).

The Vinge team advising Manor includes partner Michael Wigge and associates Peter Sundgren and Louise Markgren (M&A), partner Thomas Sjöberg and associate Johan Cederblad (Real Estate & Environmental), and associate Albert Wållgren (Banking & Finance).

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025